Recent Pfizer Press Releases

  • 7/20/18 4:24 pm EDT

    NIVESTYM™, a biosimilar to Neupogen ® (filgrastim), is Pfizer’s fourth biosimilar to be approved by the FDA

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NIVESTYM™ (filgrastim-aafi), a biosimilar to Neupogen1 (filgrastim), for all eligible indications of the reference product. “The FDA approval of NIVESTYM marks an important step in helping expand access to critical treatment options for patients with neutropenia, many of whom have cancer and can be hospitalized formore...
  • 7/16/18 10:31 am EDT

    Phase 3 lead-in study initiated following completion of the transfer of Spark Therapeutics’ hemophilia B gene therapy program to Pfizer

    NEW YORK & PHILADELPHIA--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in the usual care setting. The factor IX prophylaxis efficacy data obtained in the lead-in study will serve as the within-subject control group for those patients that enroll into the nextmore...
  • 7/13/18 2:30 pm EDT

    First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC

    TOKYO & NEW YORK--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide), following FDA Priority Review designation, based on results from the Phase 3 PROSPER trial. The FDA action broadens the indication for XTANDI to men with castration-resistant prostate cancer (more...
  • 7/11/18 6:45 am EDT

    New Hospital Business unit created within Innovative Medicines to focus on significant role of hospitals in healthcare systems

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced it will organize the company into three businesses: a science-based Innovative Medicines business which will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables; an off-patent branded and generic Established Medicines business operating with substantial autonomy within Pfizer and a Consumer Healthcare business. These changes will be effective at the beginningmore...
  • 6/28/18 1:49 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.1 XELJANZ is the first and only oral Janus kinase (JAK) inhibitor tomore...
  • 6/28/18 12:20 pm EDT
    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 34-cent third-quarter 2018 dividend on the company’s common stock, payable September 4, 2018, to shareholders of record at the close of business on August 3, 2018. The third-quarter 2018 cash dividend will be the 319th consecutive quarterly dividend paid by Pfizer. Working together for a healthier world® At Pfizer, we apply science and our global resources to bringmore...
  • 6/27/18 8:00 am EDT

    Submission Based on Data from Randomized Phase 2 Trial, Which Showed Glasdegib in Combination with Chemotherapy Nearly Doubled Overall Survival Compared to Chemotherapy Alone

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application and granted Priority Review designation for glasdegib, an investigational oral smoothened (SMO) inhibitor, being evaluated for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC), a type of chemotherapy. “Patients with acutemore...
  • 6/25/18 8:00 am EDT
    • Results show a positive trend in the secondary endpoint of overall survival, though not reaching statistical significance
    • IBRANCE is approved worldwide in combination with fulvestrant based on compelling results from the primary endpoint of progression-free survival
    NEW YORK--(BUSINESS WIRE)--Pfizer today announced overall survival (OS) results from the Phase 3 PALOMA-3 trial, which evaluated IBRANCE® (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease has progressed after prior endocrine therapy. The results demonstrated a positive trend in the hazard ratiomore...
  • 6/19/18 10:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 31, 2018. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.more...
  • 6/12/18 7:00 am EDT

    Drug Donation Supports the World Health Organization (WHO) Comprehensive Global Health Strategy to Eliminate Trachoma which Disproportionally Affects the Poorest of the Poor

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today it will extend its donation of the antibiotic Zithromax® (azithromycin) to the International Trachoma Initiative through 2025, building on the company’s 20-years of work to help eliminate the world’s leading infectious cause of blindness. Approximately 163 million people are at risk of developing the disease and this recommitment ensures that Pfizer, through the International Trachoma Initiative (ITI), will continuemore...